AstraZeneca (AZN) announced results from the BaxHTN Phase III trial showed baxdrostat at two doses demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients with uncontrolled or treatment resistant hypertension received baxdrostat or placebo on top of standard of care. Baxdrostat was generally well tolerated with a favorable safety profile. The data will be shared with regulatory authorities around the world and presented in a late-breaking Hot Line session at the European Society of Cardiology Congress in August.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s Promising BaxHTN Trial and Market Potential Drive Buy Rating
- AstraZeneca’s Promising Growth: Buy Rating Backed by Strong Phase 3 Results and Strategic Pipeline Developments
- AstraZeneca’s SERENA-1 Study: A New Hope for Advanced Breast Cancer Treatment
- AstraZeneca Completes Key Study on Asthma and COPD Diagnostics
- AstraZeneca’s Acalabrutinib Study: A Potential Game-Changer in Cancer Treatment